362 related articles for article (PubMed ID: 10219094)
1. Activity of recombinant HIV-1 integrase on mini-HIV DNA.
Cherepanov P; Surratt D; Toelen J; Pluymers W; Griffith J; De Clercq E; Debyser Z
Nucleic Acids Res; 1999 May; 27(10):2202-10. PubMed ID: 10219094
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human immunodeficiency virus type 1 integrase exhibits a capacity for full-site integration in vitro that is comparable to that of purified preintegration complexes from virus-infected cells.
Sinha S; Grandgenett DP
J Virol; 2005 Jul; 79(13):8208-16. PubMed ID: 15956566
[TBL] [Abstract][Full Text] [Related]
3. The use of a new in vitro reaction substrate reproducing both U3 and U5 regions of the HIV-1 3'-ends increases the correlation between the in vitro and in vivo effects of the HIV-1 integrase inhibitors.
Tramontano E; Onidi L; Esposito F; Badas R; La Colla P
Biochem Pharmacol; 2004 May; 67(9):1751-61. PubMed ID: 15081874
[TBL] [Abstract][Full Text] [Related]
4. [Interactions of HIV-1 DNA heterocyclic bases with viral DNA].
Agapkina IuIu; Tashlitskiĭ VN; Deprez E; Brochon JC; Shugaliĭ AV; Mouscadet JF; Gottikh MB
Mol Biol (Mosk); 2004; 38(5):848-57. PubMed ID: 15554187
[TBL] [Abstract][Full Text] [Related]
5. Two-long terminal repeat (LTR) DNA circles are a substrate for HIV-1 integrase.
Richetta C; Thierry S; Thierry E; Lesbats P; Lapaillerie D; Munir S; Subra F; Leh H; Deprez E; Parissi V; Delelis O
J Biol Chem; 2019 May; 294(20):8286-8295. PubMed ID: 30971426
[TBL] [Abstract][Full Text] [Related]
6. Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors.
Dicker IB; Samanta HK; Li Z; Hong Y; Tian Y; Banville J; Remillard RR; Walker MA; Langley DR; Krystal M
J Biol Chem; 2007 Oct; 282(43):31186-96. PubMed ID: 17715137
[TBL] [Abstract][Full Text] [Related]
7. Both substrate and target oligonucleotide sequences affect in vitro integration mediated by human immunodeficiency virus type 1 integrase protein produced in Saccharomyces cerevisiae.
Leavitt AD; Rose RB; Varmus HE
J Virol; 1992 Apr; 66(4):2359-68. PubMed ID: 1548767
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the integrase of human immunodeficiency virus (HIV) type 1 by anti-HIV plant proteins MAP30 and GAP31.
Lee-Huang S; Huang PL; Huang PL; Bourinbaiar AS; Chen HC; Kung HF
Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8818-22. PubMed ID: 7568024
[TBL] [Abstract][Full Text] [Related]
9. Quantitative in vitro assay for human immunodeficiency virus deoxyribonucleic acid integration.
Carteau S; Mouscadet JF; Goulaouic H; Subra F; Auclair C
Arch Biochem Biophys; 1993 Feb; 300(2):756-60. PubMed ID: 8434953
[TBL] [Abstract][Full Text] [Related]
10. Probing of HIV-1 integrase/DNA interactions using novel analogs of viral DNA.
Agapkina J; Smolov M; Barbe S; Zubin E; Zatsepin T; Deprez E; Le Bret M; Mouscadet JF; Gottikh M
J Biol Chem; 2006 Apr; 281(17):11530-40. PubMed ID: 16500899
[TBL] [Abstract][Full Text] [Related]
11. The HIV-1 integrase monomer induces a specific interaction with LTR DNA for concerted integration.
Pandey KK; Bera S; Grandgenett DP
Biochemistry; 2011 Nov; 50(45):9788-96. PubMed ID: 21992419
[TBL] [Abstract][Full Text] [Related]
12. Specific and independent recognition of U3 and U5 att sites by human immunodeficiency virus type 1 integrase in vivo.
Masuda T; Kuroda MJ; Harada S
J Virol; 1998 Oct; 72(10):8396-402. PubMed ID: 9733892
[TBL] [Abstract][Full Text] [Related]
13. Substrate specificity of recombinant human immunodeficiency virus integrase protein.
LaFemina RL; Callahan PL; Cordingley MG
J Virol; 1991 Oct; 65(10):5624-30. PubMed ID: 1895409
[TBL] [Abstract][Full Text] [Related]
14. Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction.
Esposito D; Craigie R
EMBO J; 1998 Oct; 17(19):5832-43. PubMed ID: 9755183
[TBL] [Abstract][Full Text] [Related]
15. Peptides derived from HIV-1 integrase that bind Rev stimulate viral genome integration.
Levin A; Hayouka Z; Helfer M; Brack-Werner R; Friedler A; Loyter A
PLoS One; 2009; 4(1):e4155. PubMed ID: 19127291
[TBL] [Abstract][Full Text] [Related]
16. In vitro assays for activities of retroviral integrase.
Chow SA
Methods; 1997 Aug; 12(4):306-17. PubMed ID: 9245611
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a replication-defective human immunodeficiency virus type 1 att site mutant that is blocked after the 3' processing step of retroviral integration.
Chen H; Engelman A
J Virol; 2000 Sep; 74(17):8188-93. PubMed ID: 10933731
[TBL] [Abstract][Full Text] [Related]
18. Development of a fluorescence-based HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors.
Han YS; Xiao WL; Quashie PK; Mesplède T; Xu H; Deprez E; Delelis O; Pu JX; Sun HD; Wainberg MA
Antiviral Res; 2013 Jun; 98(3):441-8. PubMed ID: 23583286
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 integrase crosslinked oligomers are active in vitro.
Faure A; Calmels C; Desjobert C; Castroviejo M; Caumont-Sarcos A; Tarrago-Litvak L; Litvak S; Parissi V
Nucleic Acids Res; 2005; 33(3):977-86. PubMed ID: 15718297
[TBL] [Abstract][Full Text] [Related]
20. Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions.
Svarovskaia ES; Barr R; Zhang X; Pais GC; Marchand C; Pommier Y; Burke TR; Pathak VK
J Virol; 2004 Apr; 78(7):3210-22. PubMed ID: 15016842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
